More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments

A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news